Corcept Therapeutics

Key Accounts Manager, Southeast

Remote

Not SpecifiedCompensation
Junior (1 to 2 years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceuticals, BiotechnologyIndustries

Requirements

Candidates should possess experience working in tertiary centers with a specialty in endocrinology, orphan disease, or other specialized markets, and demonstrated experience working with regional- and national-level Key Opinion Leaders (KOLs).

Responsibilities

The Key Accounts Manager will develop and execute an ethical individualized strategy to drive market development/disease awareness for key tertiary centers, always leading with a patient-focused approach aligned to current CS guidelines and approved supporting data, educating target physicians on the latest data and developments in hypercortisolism, regularly attending Endocrinology grand rounds sessions and conferences, partnering with Endocrinology fellowship programs, bridging communication gaps amongst target physician specialties, identifying and collaborating with KOLs, functioning as a liaison, and collaborating with sales counterparts and internal stakeholders to drive market growth within compliance guidelines.

Skills

Endocrinology
KOL engagement
Market development
Disease awareness
Physician education
Conference participation
Stakeholder collaboration
Compliance adherence

Corcept Therapeutics

Develops cortisol modulators for medical conditions

About Corcept Therapeutics

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Key Metrics

Menlo Park, CaliforniaHeadquarters
1998Year Founded
$39.7MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees

Benefits

Remote Work Options
Flexible Work Hours

Risks

Teva's antitrust lawsuit could lead to legal expenses and market share loss.
Heavy reliance on Korlym makes Corcept vulnerable to market fluctuations.
Recent investments may pressure Corcept for short-term financial performance, impacting R&D.

Differentiation

Corcept specializes in cortisol modulation, a niche with few direct competitors.
Korlym is the first FDA-approved treatment for Cushing's syndrome, a significant market advantage.
Corcept's extensive R&D has led to the discovery of over 1,000 selective cortisol modulators.

Upsides

Increased interest in cortisol therapies for mental health boosts Corcept's R&D prospects.
Advancements in drug delivery systems could enhance Corcept's product efficacy.
The FDA's fast-track designation supports Corcept's innovative cortisol-related treatments.

Land your dream remote job 3x faster with AI